← Back to search
ARKANSAS CHILDREN'S RESEARCH INSTITUTE
LITTLE ROCK, AR, 72202
UnclaimedClaim this profile (free)
Subcontracting experience
10 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | THIS SUBAWARD IS TO SUPPORT THE MATIC-2 CLINICAL TRIAL, WHICH EXAMINES THE EFFECTIVENESS, SAFETY AND MECHANISMS BETWEEN MULTIPLE RESUSCITATION PRACTICES IN CHILDREN WITH LIFE THREATENING BLEEDING FROM TRAUMATIC INJURY AWD00008169-9 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $256,590 | Jul 29, 2026 | — – — |
| Subcontractor | Department of Defense | ACRI WILL HAVE IDENTIFIED WHETHER ERTAPENEM MAINTAINS INCREASED LOCAL CONCENTRATION WITHIN THE ISCHEMIC LIMB AS COMPARED WITH THE CONTRALATERAL PERFUSED LIMB AND SYSTEMIC CIRCULATION DURING THE TOURNIQUET TIME. GS.10000107.ACRI Parent award context Parent award agency: Department of Defense · Defense Health Agency Parent award NAICS: 541715 Parent award performance state: CO Parent award description: TDA'S SBIR PHASE II H2-0747 ENHANCED COMBAT TOURNIQUET WITH MODULAR WOUND INFECTION PREVENTION CAPABILITIES View parent award on USAspending | — | $117,838 | Feb 13, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | TRAUMA IS THE MOST COMMON CAUSE OF DEATH FOR CHILDREN1. BLEEDING IS THE LEADING
CAUSE OF PREVENTABLE DEATH IN INJURED CHILDREN2-4. MORTALITY RATES AT 28-DAYS IN INJURED CHILDREN WITH
LIFE THREATENING HEMORRHAGE (LTH) RANGE FROM 36-50%,5-7 APPROXIMATELY TWICE THAT OF INJURED ADULTS
(21-24%)6,7
. DESPITE THE FACT THAT CHILDREN€„¢S COAGULATION AND PHYSIOLOGIC RESPONSE TO BLEEDING
DIFFERS FROM ADULTS8-11, PEDIATRIC TRAUMA RESUSCITATION PRACTICE GUIDELINES ARE DERIVED FROM ADULT DATA
DUE TO A LACK OF HIGH QUALITY RESEARCH IN CHILDREN12,13.
HEMORRHAGE IS INITIALLY ADDRESSED BY HEMOSTATIC RESUSCITATION14-19, A STRATEGY THAT RESTORES
ADEQUATE PERFUSION AND MITIGATES THE EFFECTS OF TRAUMA-INDUCED COAGULOPATHY (TIC). THE CURRENT
STANDARD OF CARE IS TO TRANSFUSE COMPONENT THERAPY (CT) (I.E., RBC, FFP, PLATELETS) IN BALANCED
RATIOS. 20,21 HOWEVER, THE MIXTURE OF CT IS MORE DILUTE WITH INCREASED ANTICOAGULANTS AND ADDITIVE
SOLUTIONS 22 COMPARED TO WHOLE BLOOD. THE NEED TO OPTIMIZE BALANCED RESUSCITATION HAS LED TO THE
CLINICAL USE OF COLD-STORED LOW TITER GROUP O WHOLE BLOOD (LTOWB) 23, WHICH HAS MULTIPLE POTENTIAL
ADVANTAGES OVER CT (IMPROVED OXYGEN DELIVERY, HEMOSTATIC FUNCTION22,24-30, EASE OF
ADMINISTRATION,31 32 AND REDUCED RISK OF FATAL HEMOLYTIC REACTIONS AND DONOR EXPOSURES33).
IN CHILDREN WITH LTH FROM TRAUMA, LTOWB COMPARED TO CT MAY DECREASE TOTAL BLOOD PRODUCTS
TRANSFUSED, IMPROVE OXYGEN DELIVERY, COAGULATION, AND 72-HOUR AND 28-DAY SURVIVAL WITHOUT
INCREASING THE RISK OF HEMOLYSIS AND ORGAN FAILURE34-36. THOUGH PROMISING, THE DATA ARE LIMITED BY
SINGLE-CENTER STUDIES AND SMALL COHORT SIZE; NO MULTICENTER TRIALS COMPARE LTOWB TO CT IN PEDIATRIC
TRAUMA PATIENTS. TRANEXAMIC ACID (TXA) IS AN ANTIFIBRINOLYTIC THAT HAS BEEN PROVEN TO IMPROVE
SURVIVAL IN SEVERELY INJURED ADULT TRAUMA PATIENTS AND THERE IS OBSERVATIONAL DATA IT IS INDEPENDENTLY
ASSOCIATED WITH IMPROVED SURVIVAL IN CHILDREN37. THE TIC TOC TRIAL WILL EXAMINE THE EFFECTIVENESS
AND SAFETY OF TXA IN CHILDREN WITH TRAUMATIC BLEEDING38.
HEMORRHAGIC SHOCK PRECIPITATES THE BODY€„¢S COMPLEX ENDOGENOUS RESPONSE TO HYPOPERFUSION AND
INJURY. WE HAVE DEMONSTRATED THAT TIC IS COMMON IN INJURED CHILDREN AND HIGHLY ASSOCIATED WITH
DEATH, DISABILITY, ORGAN FAILURE AND NEED FOR GREATER VOLUMES OF BLOOD PRODUCTS.
39-43 DESPITE THE
CRITICAL IMPORTANCE OF PEDIATRIC TIC, DATA REGARDING UNDERLYING MECHANISMS ARE SPARSE. TO OPTIMIZE
TRANSFUSION STRATEGIES INCHILDREN WITH TRAUMATIC HEMORRHAGIC SHOCK, IT IS ESSENTIAL TO INVESTIGATE THE
MECHANISMS OF TIC COMPREHENSIVELY.WE PROPOSE THE MASSIVE TRANSFUSION IN CHILDREN-2 (MATIC-2) TRIAL, A PRAGMATIC, BAYESIAN, GROUP
SEQUENTIAL, COMBINED NON-INFERIORITY/SUPERIORITY, RANDOMIZED, CONTROLLED, MULTICENTER, PHASE III,
PLATFORM TRIAL TO EXAMINE THE EFFECTIVENESS AND SAFETY OF LTOWB RELATIVE TO STANDARD CT IN 1000
DOCUSIGN ENVELOPE ID: CD235578-BBE9-4B23-927D-107F20895C9F DOCUSIGN ENVELOPE ID: A0A11664-A9BF-4977-8D06-2C403DCC96CE
SUBCONTRACT NO. AWD00008169-9
SUBCONTRACTOR: ARKANSAS CHILDREN€„¢S RESEARCH INSTITUTE
PAGE 23 OF 26
CHILDREN AT 18 US ACADEMIC PEDIATRIC TRAUMA CENTERS. MECHANISMS OF TIC AND RESUSCITATION EFFECTS
WILL ALSO BE INVESTIGATED.
AIM 1:€¯ASSESS€¯THE EFFECT OF LTOWB VERSUS CT ON CLINICAL OUTCOMES.€¯ H1: WE HYPOTHESIZE THAT
COMPARED TO CT, LTOWB IS A) NON-INFERIOR AND/OR B) SUPERIOR FOR 24-HOUR MORTALITY.
AIM 2: ASSESS THE SAFETY OF LTOWB VERSUS CT. H2: WE HYPOTHESIZE THAT LTOWB TRANSFUSION DOES NOT
INCREASE THE RISK OF ADVERSE EVENTS OR OUTCOMES COMPARED TO CT.
AIM 3: DEFINE THE MECHANISMS OF TIC AND ASSESS THE BIOLOGIC EFFECTS OF TRANSFUSION STRATEGIES ON
MEASURES OF OXYGEN DELIVERY, HEMOSTASIS, IMMUNE AND ENDOTHELIAL FUNCTION. H3: WE HYPOTHESIZE THAT
LTOWB IS SUPERIOR TO CT IN CORRECTING THE HYPOPERFUSION, ENDOTHELIAL INJURY, IMMUNE DYSFUNCTION, AND
DYSREGULATION OF COAGULATION AND FIBRINOLYSIS PATHWAYS THAT CONTRIBUTE TO THE ETIOLOGY OF TIC IN CHILDREN.
THIS IS THE FIRST DEFINITIVE TRIAL EXAMINING LTOWB I AWD00008169-9 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $211,611 | Jul 17, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | TRAUMA IS THE MOST COMMON CAUSE OF DEATH FOR CHILDREN1. BLEEDING IS THE LEADING
CAUSE OF PREVENTABLE DEATH IN INJURED CHILDREN2-4. MORTALITY RATES AT 28-DAYS IN INJURED CHILDREN WITH
LIFE THREATENING HEMORRHAGE (LTH) RANGE FROM 36-50%,5-7 APPROXIMATELY TWICE THAT OF INJURED ADULTS
(21-24%)6,7
. DESPITE THE FACT THAT CHILDREN€„¢S COAGULATION AND PHYSIOLOGIC RESPONSE TO BLEEDING
DIFFERS FROM ADULTS8-11, PEDIATRIC TRAUMA RESUSCITATION PRACTICE GUIDELINES ARE DERIVED FROM ADULT DATA
DUE TO A LACK OF HIGH QUALITY RESEARCH IN CHILDREN12,13.
HEMORRHAGE IS INITIALLY ADDRESSED BY HEMOSTATIC RESUSCITATION14-19, A STRATEGY THAT RESTORES
ADEQUATE PERFUSION AND MITIGATES THE EFFECTS OF TRAUMA-INDUCED COAGULOPATHY (TIC). THE CURRENT
STANDARD OF CARE IS TO TRANSFUSE COMPONENT THERAPY (CT) (I.E., RBC, FFP, PLATELETS) IN BALANCED
RATIOS. 20,21 HOWEVER, THE MIXTURE OF CT IS MORE DILUTE WITH INCREASED ANTICOAGULANTS AND ADDITIVE
SOLUTIONS 22 COMPARED TO WHOLE BLOOD. THE NEED TO OPTIMIZE BALANCED RESUSCITATION HAS LED TO THE
CLINICAL USE OF COLD-STORED LOW TITER GROUP O WHOLE BLOOD (LTOWB) 23, WHICH HAS MULTIPLE POTENTIAL
ADVANTAGES OVER CT (IMPROVED OXYGEN DELIVERY, HEMOSTATIC FUNCTION22,24-30, EASE OF
ADMINISTRATION,31 32 AND REDUCED RISK OF FATAL HEMOLYTIC REACTIONS AND DONOR EXPOSURES33).
IN CHILDREN WITH LTH FROM TRAUMA, LTOWB COMPARED TO CT MAY DECREASE TOTAL BLOOD PRODUCTS
TRANSFUSED, IMPROVE OXYGEN DELIVERY, COAGULATION, AND 72-HOUR AND 28-DAY SURVIVAL WITHOUT
INCREASING THE RISK OF HEMOLYSIS AND ORGAN FAILURE34-36. THOUGH PROMISING, THE DATA ARE LIMITED BY
SINGLE-CENTER STUDIES AND SMALL COHORT SIZE; NO MULTICENTER TRIALS COMPARE LTOWB TO CT IN PEDIATRIC
TRAUMA PATIENTS. TRANEXAMIC ACID (TXA) IS AN ANTIFIBRINOLYTIC THAT HAS BEEN PROVEN TO IMPROVE
SURVIVAL IN SEVERELY INJURED ADULT TRAUMA PATIENTS AND THERE IS OBSERVATIONAL DATA IT IS INDEPENDENTLY
ASSOCIATED WITH IMPROVED SURVIVAL IN CHILDREN37. THE TIC TOC TRIAL WILL EXAMINE THE EFFECTIVENESS
AND SAFETY OF TXA IN CHILDREN WITH TRAUMATIC BLEEDING38.
HEMORRHAGIC SHOCK PRECIPITATES THE BODY€„¢S COMPLEX ENDOGENOUS RESPONSE TO HYPOPERFUSION AND
INJURY. WE HAVE DEMONSTRATED THAT TIC IS COMMON IN INJURED CHILDREN AND HIGHLY ASSOCIATED WITH
DEATH, DISABILITY, ORGAN FAILURE AND NEED FOR GREATER VOLUMES OF BLOOD PRODUCTS.
39-43 DESPITE THE
CRITICAL IMPORTANCE OF PEDIATRIC TIC, DATA REGARDING UNDERLYING MECHANISMS ARE SPARSE. TO OPTIMIZE
TRANSFUSION STRATEGIES INCHILDREN WITH TRAUMATIC HEMORRHAGIC SHOCK, IT IS ESSENTIAL TO INVESTIGATE THE
MECHANISMS OF TIC COMPREHENSIVELY.WE PROPOSE THE MASSIVE TRANSFUSION IN CHILDREN-2 (MATIC-2) TRIAL, A PRAGMATIC, BAYESIAN, GROUP
SEQUENTIAL, COMBINED NON-INFERIORITY/SUPERIORITY, RANDOMIZED, CONTROLLED, MULTICENTER, PHASE III,
PLATFORM TRIAL TO EXAMINE THE EFFECTIVENESS AND SAFETY OF LTOWB RELATIVE TO STANDARD CT IN 1000
DOCUSIGN ENVELOPE ID: CD235578-BBE9-4B23-927D-107F20895C9F DOCUSIGN ENVELOPE ID: A0A11664-A9BF-4977-8D06-2C403DCC96CE
SUBCONTRACT NO. AWD00008169-9
SUBCONTRACTOR: ARKANSAS CHILDREN€„¢S RESEARCH INSTITUTE
PAGE 23 OF 26
CHILDREN AT 18 US ACADEMIC PEDIATRIC TRAUMA CENTERS. MECHANISMS OF TIC AND RESUSCITATION EFFECTS
WILL ALSO BE INVESTIGATED.
AIM 1:€¯ASSESS€¯THE EFFECT OF LTOWB VERSUS CT ON CLINICAL OUTCOMES.€¯ H1: WE HYPOTHESIZE THAT
COMPARED TO CT, LTOWB IS A) NON-INFERIOR AND/OR B) SUPERIOR FOR 24-HOUR MORTALITY.
AIM 2: ASSESS THE SAFETY OF LTOWB VERSUS CT. H2: WE HYPOTHESIZE THAT LTOWB TRANSFUSION DOES NOT
INCREASE THE RISK OF ADVERSE EVENTS OR OUTCOMES COMPARED TO CT.
AIM 3: DEFINE THE MECHANISMS OF TIC AND ASSESS THE BIOLOGIC EFFECTS OF TRANSFUSION STRATEGIES ON
MEASURES OF OXYGEN DELIVERY, HEMOSTASIS, IMMUNE AND ENDOTHELIAL FUNCTION. H3: WE HYPOTHESIZE THAT
LTOWB IS SUPERIOR TO CT IN CORRECTING THE HYPOPERFUSION, ENDOTHELIAL INJURY, IMMUNE DYSFUNCTION, AND
DYSREGULATION OF COAGULATION AND FIBRINOLYSIS PATHWAYS THAT CONTRIBUTE TO THE ETIOLOGY OF TIC IN CHILDREN.
THIS IS THE FIRST DEFINITIVE TRIAL EXAMINING LTOWB I AWD00008169-9 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $211,611 | Jul 17, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | TRAUMA IS THE MOST COMMON CAUSE OF DEATH FOR CHILDREN1. BLEEDING IS THE LEADING
CAUSE OF PREVENTABLE DEATH IN INJURED CHILDREN2-4. MORTALITY RATES AT 28-DAYS IN INJURED CHILDREN WITH
LIFE THREATENING HEMORRHAGE (LTH) RANGE FROM 36-50%,5-7 APPROXIMATELY TWICE THAT OF INJURED ADULTS
(21-24%)6,7
. DESPITE THE FACT THAT CHILDREN€„¢S COAGULATION AND PHYSIOLOGIC RESPONSE TO BLEEDING
DIFFERS FROM ADULTS8-11, PEDIATRIC TRAUMA RESUSCITATION PRACTICE GUIDELINES ARE DERIVED FROM ADULT DATA
DUE TO A LACK OF HIGH QUALITY RESEARCH IN CHILDREN12,13.
HEMORRHAGE IS INITIALLY ADDRESSED BY HEMOSTATIC RESUSCITATION14-19, A STRATEGY THAT RESTORES
ADEQUATE PERFUSION AND MITIGATES THE EFFECTS OF TRAUMA-INDUCED COAGULOPATHY (TIC). THE CURRENT
STANDARD OF CARE IS TO TRANSFUSE COMPONENT THERAPY (CT) (I.E., RBC, FFP, PLATELETS) IN BALANCED
RATIOS. 20,21 HOWEVER, THE MIXTURE OF CT IS MORE DILUTE WITH INCREASED ANTICOAGULANTS AND ADDITIVE
SOLUTIONS 22 COMPARED TO WHOLE BLOOD. THE NEED TO OPTIMIZE BALANCED RESUSCITATION HAS LED TO THE
CLINICAL USE OF COLD-STORED LOW TITER GROUP O WHOLE BLOOD (LTOWB) 23, WHICH HAS MULTIPLE POTENTIAL
ADVANTAGES OVER CT (IMPROVED OXYGEN DELIVERY, HEMOSTATIC FUNCTION22,24-30, EASE OF
ADMINISTRATION,31 32 AND REDUCED RISK OF FATAL HEMOLYTIC REACTIONS AND DONOR EXPOSURES33).
IN CHILDREN WITH LTH FROM TRAUMA, LTOWB COMPARED TO CT MAY DECREASE TOTAL BLOOD PRODUCTS
TRANSFUSED, IMPROVE OXYGEN DELIVERY, COAGULATION, AND 72-HOUR AND 28-DAY SURVIVAL WITHOUT
INCREASING THE RISK OF HEMOLYSIS AND ORGAN FAILURE34-36. THOUGH PROMISING, THE DATA ARE LIMITED BY
SINGLE-CENTER STUDIES AND SMALL COHORT SIZE; NO MULTICENTER TRIALS COMPARE LTOWB TO CT IN PEDIATRIC
TRAUMA PATIENTS. TRANEXAMIC ACID (TXA) IS AN ANTIFIBRINOLYTIC THAT HAS BEEN PROVEN TO IMPROVE
SURVIVAL IN SEVERELY INJURED ADULT TRAUMA PATIENTS AND THERE IS OBSERVATIONAL DATA IT IS INDEPENDENTLY
ASSOCIATED WITH IMPROVED SURVIVAL IN CHILDREN37. THE TIC TOC TRIAL WILL EXAMINE THE EFFECTIVENESS
AND SAFETY OF TXA IN CHILDREN WITH TRAUMATIC BLEEDING38.
HEMORRHAGIC SHOCK PRECIPITATES THE BODY€„¢S COMPLEX ENDOGENOUS RESPONSE TO HYPOPERFUSION AND
INJURY. WE HAVE DEMONSTRATED THAT TIC IS COMMON IN INJURED CHILDREN AND HIGHLY ASSOCIATED WITH
DEATH, DISABILITY, ORGAN FAILURE AND NEED FOR GREATER VOLUMES OF BLOOD PRODUCTS.
39-43 DESPITE THE
CRITICAL IMPORTANCE OF PEDIATRIC TIC, DATA REGARDING UNDERLYING MECHANISMS ARE SPARSE. TO OPTIMIZE
TRANSFUSION STRATEGIES INCHILDREN WITH TRAUMATIC HEMORRHAGIC SHOCK, IT IS ESSENTIAL TO INVESTIGATE THE
MECHANISMS OF TIC COMPREHENSIVELY.WE PROPOSE THE MASSIVE TRANSFUSION IN CHILDREN-2 (MATIC-2) TRIAL, A PRAGMATIC, BAYESIAN, GROUP
SEQUENTIAL, COMBINED NON-INFERIORITY/SUPERIORITY, RANDOMIZED, CONTROLLED, MULTICENTER, PHASE III,
PLATFORM TRIAL TO EXAMINE THE EFFECTIVENESS AND SAFETY OF LTOWB RELATIVE TO STANDARD CT IN 1000
DOCUSIGN ENVELOPE ID: CD235578-BBE9-4B23-927D-107F20895C9F DOCUSIGN ENVELOPE ID: A0A11664-A9BF-4977-8D06-2C403DCC96CE
SUBCONTRACT NO. AWD00008169-9
SUBCONTRACTOR: ARKANSAS CHILDREN€„¢S RESEARCH INSTITUTE
PAGE 23 OF 26
CHILDREN AT 18 US ACADEMIC PEDIATRIC TRAUMA CENTERS. MECHANISMS OF TIC AND RESUSCITATION EFFECTS
WILL ALSO BE INVESTIGATED.
AIM 1:€¯ASSESS€¯THE EFFECT OF LTOWB VERSUS CT ON CLINICAL OUTCOMES.€¯ H1: WE HYPOTHESIZE THAT
COMPARED TO CT, LTOWB IS A) NON-INFERIOR AND/OR B) SUPERIOR FOR 24-HOUR MORTALITY.
AIM 2: ASSESS THE SAFETY OF LTOWB VERSUS CT. H2: WE HYPOTHESIZE THAT LTOWB TRANSFUSION DOES NOT
INCREASE THE RISK OF ADVERSE EVENTS OR OUTCOMES COMPARED TO CT.
AIM 3: DEFINE THE MECHANISMS OF TIC AND ASSESS THE BIOLOGIC EFFECTS OF TRANSFUSION STRATEGIES ON
MEASURES OF OXYGEN DELIVERY, HEMOSTASIS, IMMUNE AND ENDOTHELIAL FUNCTION. H3: WE HYPOTHESIZE THAT
LTOWB IS SUPERIOR TO CT IN CORRECTING THE HYPOPERFUSION, ENDOTHELIAL INJURY, IMMUNE DYSFUNCTION, AND
DYSREGULATION OF COAGULATION AND FIBRINOLYSIS PATHWAYS THAT CONTRIBUTE TO THE ETIOLOGY OF TIC IN CHILDREN.
THIS IS THE FIRST DEFINITIVE TRIAL EXAMINING LTOWB I AWD00008169-9 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541715 Parent award performance state: PA Parent award description: PROVIDE DEFINITIVE EVIDENCE ON THE EFFECTIVENESS, SAFETY, AND MECHANISMS OF LOW TITER GROUP O WHOLE BLOOD (LTOWB) AND TRANEXAMIC ACID (TXA) AS RESUSCITATION STRATEGIES FOR THE TREATMENT OF LIFE-THREATENING BLEEDING SECONDARY TO TRAUMATIC INJURY IN CH View parent award on USAspending | — | $211,611 | Jul 17, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | PARTICIPATE IN CLINICAL PROTOCOL SITE DEVELOPMENT TELECONFERENCES, BEGIN PATIENT SCREENING AND ENROLLMENT OF SUBJECTS, AND COMPLETE FINAL CLINICAL STUDY PROCEDURES AND FOLLOW-UP FOR ENROLLED SUBJECTS. 000509729-SC003-SNO-A08 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: AL Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | -$41,000 | Feb 22, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | PARTICIPATE IN CLINICAL PROTOCOL SITE DEVELOPMENT TELECONFERENCES, BEGIN PATIENT SCREENING AND ENROLLMENT OF SUBJECTS, AND COMPLETE FINAL CLINICAL STUDY PROCEDURES AND FOLLOW-UP FOR ENROLLED SUBJECTS. 000509729-SC003-SNO-A07 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: AL Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | -$36,000 | Aug 9, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | PARTICIPATE IN CLINICAL PROTOCOL AND SITE DEVELOPMENT TELECONFERENCES; COLLECT AND PROVIDE TO UAB CENTRAL UNIT ALL SUPPORTING REGULATORY DOCUMENTS FOR CONDUCTING THE STUDY; COMPLETE NECESSARY TRAINING; PROVIDE IRB DOCUMENTATION TO UAB CENTRAL UNIT; BEGIN, TRACK, AND DOCUMENT PATIENT SCREENING AND ENROLLMENT OF SUBJECTS IN ACCORDANCE WITH THE MOST CURRENT APPROVED PROTOCOL; COMPLETE STUDY REQUIRED CLINICAL PROCEDURES; COMPLETE FINAL CLINICAL STUDY PROCEDURES AND FOLLOW-UP FOR ENROLLED SUBJECTS IN ACCORDANCE WITH THE PROTOCOL; SUBMIT ALL REQUIRED DATA TO UAB; AND COMPLETE FINAL CLOSEOUT ACTIVITIES. 000509734-SC028-SNO-A01 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: AL Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $25,750 | Jun 14, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | PARTICIPATE IN CLINICAL PROTOCOL AND SITE DEVELOPMENT TELECONFERENCES; COLLECT AND PROVIDE TO UAB CENTRAL UNIT ALL SUPPORTING REGULATORY DOCUMENTS FOR CONDUCTING THE STUDY; COMPLETE NECESSARY TRAINING; PROVIDE IRB DOCUMENTATION TO UAB CENTRAL UNIT; BEGIN, TRACK, AND DOCUMENT PATIENT SCREENING AND ENROLLMENT OF SUBJECTS IN ACCORDANCE WITH THE MOST CURRENT APPROVED PROTOCOL; COMPLETE STUDY REQUIRED CLINICAL PROCEDURES; COMPLETE FINAL CLINICAL STUDY PROCEDURES AND FOLLOW-UP FOR ENROLLED SUBJECTS IN ACCORDANCE WITH THE PROTOCOL; SUBMIT ALL REQUIRED DATA TO UAB; AND COMPLETE FINAL CLOSEOUT ACTIVITIES. 000509734-028 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: AL Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $99,102 | Nov 8, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | PARTICIPATE IN CLINICAL PROTOCOL AND SITE DEVELOPMENT, BEGIN PATIENT SCREENING AND ENROLLMENT OF SUBJECTS, AND COMPLETE STUDY REQUIRED CLINICAL PROCEDURES. 000529729-003 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: AL Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $57,621 | Feb 21, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.